Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15321056 | 0.84 | TAAR1 (0.43) | TAAR1CA12CA1CA2CA9 | |
| SCHEMBL533866 | 0.84 | MTNR1A (0.61) | TAAR1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL29686650 | 0.84 | MTNR1A (0.61) | TAAR1KMT2AMTNR1AMTNR1BLMNA | |
| SCHEMBL6700589 | 0.81 | MTNR1A (0.46) | CA12CA2CA9KMT2AHIF1A | |
| SCHEMBL2456852 | 0.81 | KMT2A (0.58) | CA12CA1CA2CA9KMT2A | |
| SCHEMBL28710994 | 0.81 | NLRP3 (0.61) | TAAR1NLRP3POLBALDH1A1LMNA | |
| SCHEMBL12851863 | 0.81 | TAAR1 (0.56) | TAAR1GPR52CA12CA1CA2 | |
| SCHEMBL30878491 | 0.81 | TAAR1 (0.56) | TAAR1CA12CA1CA2CA9 | |
| SCHEMBL33530786 | 0.81 | TAAR1 (0.56) | TAAR1CA12CA1CA2CA9 | |
| SCHEMBL33531701 | 0.80 | TAAR1 (0.50) | TAAR1GPR52CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | SANOFI (FR) | 2024-04-18 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| EP-4263493-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | Sanofi (FR) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022133027-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI (FR) | 2022-06-23 | — | — | WO | disclosed |
| EP-3601267-A1 | 2-METHYL-QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2020-02-05 | — | — | EP | disclosed |
| US-10377748-B2 | Hepatitis B core protein modulators | ASSEMBLY BIOSCIENCES, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| WO-2018172250-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-27 | — | — | WO | disclosed |
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-08-09 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-2185511-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| EP-2155734-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009044019-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
| WO-2008144223-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| CN-100347151-C | Novel aminobenzophenones | LEO PHARMA AS (DK) | 2007-11-07 | — | — | CN | disclosed |
| US-7034015-B2 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2006-04-25 | — | — | US | disclosed |
| EP-1423356-A2 | NOVEL AMINOBENZOEPHENONES | Leo Pharma A/S (DK) | 2004-06-02 | — | — | EP | disclosed |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | LEO PHARMA A/S (DK) | 2003-06-26 | — | — | US | disclosed |
| WO-2003018535-A2 | NOVEL AMINOBENZOEPHENONES | LEO PHARMA A/S (DK) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | TAAR1 3513/4885GPR52 1678/4885CA12 4706/4885 |
| US-20120202837-A1 | SPIROCYCLIC PIPERIDINE DERIVATIVES USEFUL AS RENIN INHIBITORS | REN, AGTR1, AGTR2 | TAAR1 1252/4885GPR52 2240/4885CA12 4012/4885 |
| US-10377748-B2 | Hepatitis B core protein modulators | HAVCR2, FABP1, MAVS | TAAR1 4479/4885GPR52 629/4885CA12 3562/4885 |
| US-20240124408-A1 | Substituted Cyclohexanecarboxamides, Their Preparation and Their Therapeutic Application | TRPM8, TAS2R8, TRPM7 | TAAR1 130/4885GPR52 103/4885CA12 1293/4885 |
| US-20030119902-A1 | Interleukin 1 beta and tumour necrosis factor alpha inhibitors | IL1B, IL1A, TNF | TAAR1 3169/4885GPR52 3405/4885CA12 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.